Biopharma Board Governance
← All Articles

The Board Meeting Itself: Packets, Agendas, Executive Sessions, and Minutes

|Lawrence Fine

Almost everything else in board governance is infrastructure for a single recurring event. Composition determines who is in the room. Committees determine how the work is divided before anyone gets there. The chair role determines who runs it. All of it exists so that, six or eight times a year, a group of people can sit down and do the thing a board actually does: understand the company's situation accurately and make decisions about it.

And yet the meeting itself is the part almost nobody designs. Most clinical-stage boards inherit a format from whoever ran the first one, and then run that format for years. The packet arrives when it arrives. The agenda is whatever management sent. The meeting is mostly presentations. Executive session happens sometimes, awkwardly, when something is wrong. The minutes are a thin record produced by counsel some weeks later.

Each of those is a design choice, even when nobody consciously made it. This article works through them — what the packet should do, who should own the agenda, how the time in the room should actually be spent, what executive sessions are for, and why the minutes matter more than their length suggests.


The Packet Is the Meeting

The quality of a board meeting is largely determined before anyone arrives, by what was sent and when.

The most common failure is timing. A packet that arrives the night before, or the morning of, guarantees that the meeting will be spent transferring information rather than deliberating about it. Directors who have not read the material need to be told what is in it, which consumes the time that should have been spent discussing what it means. A board that is still learning the facts at the moment it is asked to decide is not deliberating; it is reacting.

The remedy is unglamorous and almost entirely a matter of discipline: the packet goes out far enough in advance that directors can genuinely read it — most boards that take this seriously settle on something like five to seven days — and it goes out on that schedule every time, not when management happens to finish. A standing deadline that is occasionally missed is a deadline. A standing deadline that is routinely missed is a culture, and it is one in which the board is structurally one step behind.

The second failure is content, and it is subtler. Management prepares board materials, and management — entirely naturally, without any intent to mislead — prepares them the way it prepares everything else: as a presentation. Presentations are built to convey a conclusion. They lead with the headline, support it, and resolve. What a board needs in order to decide is different: the underlying facts, the alternatives that were considered and set aside, the assumptions driving the recommendation, and the things that would have to be true for it to work.

A useful discipline is to require that materials distinguish clearly between three categories: information the board is receiving for awareness, matters the board is being asked to discuss, and decisions the board is being asked to make. Each requires a different depth of preparation, and conflating them is how a consequential decision ends up buried in a status update. When a decision is being sought, the materials should say so explicitly, state the recommendation, and set out the alternatives and the basis for choosing among them.

The third failure is volume. A two-hundred-page packet is not thorough; it is a way of transmitting everything while ensuring nothing is read. Material that matters should be short enough to actually be read and separated from the reference appendices that directors can consult if they want depth. The test is whether a conscientious director with two hours can finish the core materials and arrive genuinely prepared. If not, the packet has failed regardless of how complete it is.


Who Owns the Agenda

The agenda determines what the board thinks about and, by its time allocation, what the board treats as important. In most clinical-stage companies, the agenda is built by the CEO, sometimes with the chair's input, often without.

This is a structural problem, not a comment on any particular CEO. A management-built agenda will reflect management's view of what matters, which is usually operational progress, and it will naturally allocate time to the things management has prepared to present. The topics a board most needs to engage with — a decision management is uncertain about, a risk management would rather not dwell on, a strategic question with no immediate answer — are precisely the topics that are hardest for management to build an agenda around.

The agenda should be owned by the chair or lead independent director, built in consultation with the CEO. That is a small structural change with a large effect. It creates a standing conversation between the chair and the CEO about what the board needs to address, it gives the chair a legitimate basis for adding items management did not propose, and it signals that the meeting belongs to the board.

Two practical disciplines improve almost any agenda.

The first is to put the most consequential item early. Boards reliably spend their best attention on whatever comes first and their worst on whatever comes last, and operational updates have a way of migrating to the front because they feel like scene-setting. The result is that the hardest question of the meeting gets taken up at the ninety-minute mark by people who are tired and watching the clock. If the most important thing on the agenda is the go/no-go decision on the next study, that belongs near the top, with the financial and operational updates handled as pre-read and confirmed briefly.

The second is to allocate time explicitly and in proportion to consequence, rather than letting the agenda fill by convention. An item worth a real decision is worth forty-five minutes of genuine discussion. A quarterly operational update that the directors have already read is worth ten minutes of questions. Writing the time allocations on the agenda — and having the chair enforce them — is a modest act that reshapes how a board spends itself.


What Should Happen in the Room

The most common pathology of the clinical-stage board meeting is that it is a sequence of presentations. Management presents; the board asks a few questions at the end of each; the meeting ends; everyone feels it went well because the material was covered.

Covering the material is not the purpose. If the packet was sent in advance and read, the material is already covered. The purpose of the time together is the thing that cannot be done asynchronously: collective deliberation, where directors think out loud, disagree, test assumptions, and arrive somewhere the materials did not already specify.

A board that wants that has to change the ratio. The useful rule of thumb is that presentation should be the minority of the time and discussion the majority — which means management should be asked to present briefly on the assumption that the packet was read, rather than walking through slides the directors have already seen. The first time a chair says "we have all read this, so let's go straight to questions," the meeting changes character.

It also requires attention to how decisions are framed. A board asked "does anyone have concerns?" after a confident recommendation will usually produce silence, which is not agreement but the absence of a structured opportunity to disagree. A board asked "what would have to be true for this to be the wrong call?" produces something different. The chair's framing of a decision does more to determine the quality of deliberation than any amount of material.

Two other habits are worth naming because they are small and compounding. One is going around the table on consequential decisions, so that every director states a view rather than allowing the loudest two voices to stand in for the board. The other is protecting the newest or quietest director's opportunity to speak before the senior voices have set the direction — in a five-seat board where one investor director has the strongest personality, the sequence in which people speak substantially determines the outcome.


Executive Sessions

An executive session is a portion of the meeting in which some set of participants is excluded — most commonly management, sometimes everyone except the independent directors. It is among the most valuable governance tools available to a small board, and among the most poorly used.

The core problem is that many clinical-stage boards hold executive sessions only when something is wrong. If the only time management leaves the room is when the board is unhappy, then every executive session is an event, the CEO spends it anxious about what is being said, and the board becomes reluctant to call one for fear of signalling a crisis. The tool becomes unusable precisely when it is most needed.

The remedy is to make it routine. An executive session at the end of every board meeting, held whether or not there is anything particular to discuss, costs almost nothing and removes the signalling problem entirely. When it happens every time, it means nothing in itself, which is exactly what makes it available when it matters.

There are really three distinct sessions worth distinguishing. The first is the board without management, where directors can discuss the CEO's performance, their own concerns about the company, and matters that would be filtered by management's presence. The second is the independent directors alone, without investor designees, which is the venue for anything touching the divergence between fund interests and the interests of shareholders generally — a conversation that cannot honestly be had with the investor directors present. The third is the board with a specific function alone: the audit committee with the external auditor, or the board with the chief medical officer, without the CEO. That last one is uncomfortable and genuinely valuable; it is how a board learns whether the CMO's assessment of a clinical situation matches the way it has been characterized to them.

Two practices make executive sessions work. The chair should state at the start of the meeting that an executive session will be held, so it is expected rather than sprung. And the chair should give the CEO a brief, honest summary afterward of anything the CEO needs to know. A CEO who receives nothing after every executive session will fill the silence with worst-case assumptions, and the sessions will poison the chair–CEO relationship that the whole structure depends on.


The Minutes

Minutes are treated as an administrative afterthought in most small companies, often drafted weeks later by counsel from someone's notes, reviewed quickly, and approved at the following meeting with no real attention. This is a mistake, for two distinct reasons.

The first is that the minutes are the record. Years later, when a financing is challenged, a transaction is questioned, or a decision is examined in litigation or diligence, the minutes are the primary evidence of what the board actually did and why. The transactional governance questions that dominate a company's later life — whether a conflicted financing was properly approved, whether directors were disinterested, whether alternatives were genuinely considered — are all answered from the contemporaneous record or not answered at all. A board that deliberated carefully but recorded nothing has, for practical purposes, lost the benefit of having deliberated carefully.

The second is that writing the minutes well imposes a discipline on the meeting. If someone has to record what decision was made, on what basis, and who participated, then the board has to actually reach a decision rather than letting a discussion trail off into implicit consensus. A surprising number of board meetings end with everyone holding a slightly different understanding of what was decided, and minutes drafted honestly surface that immediately.

There are two failure modes, in opposite directions. Minutes that are too thin — "the board discussed the proposed financing and approved it" — record nothing useful and provide no evidence that the board engaged at all. Minutes that are too full, recording the back-and-forth of debate and attributing positions to individual directors, create a different problem: they document disagreement in a form that can be used against the company later, and they discourage candid discussion once directors realize they are being transcribed.

The workable middle records the substance without the transcript. What was presented, what alternatives were considered, what the key factors in the decision were, what was decided, who was present, who recused and why, and what materials the board relied on. Where the board made a determination that matters structurally — that certain directors were disinterested, that a committee was authorized to act — that determination should appear explicitly, because it is exactly the kind of thing that must be shown to have been made deliberately rather than assumed.

Minutes should be drafted promptly, while memory is fresh, and reviewed by the chair before circulation. A board that habitually approves minutes for a meeting four months earlier, which nobody remembers clearly, has a record nobody can vouch for.


Cadence and the Spaces Between

How often a clinical-stage board meets is less important than whether the rhythm matches what the company is actually doing. Six to eight meetings a year is common and reasonable for a company in steady development. A company approaching a data readout, running a financing, or managing a crisis needs more, and should not wait for the calendar.

The more consequential question is what happens between meetings. A board that only learns things at meetings is a board that is routinely surprised, and surprise is corrosive — it makes directors suspect they are being managed rather than informed, whether or not they are.

The norm worth establishing explicitly is that the board hears material news when it happens, not at the next scheduled meeting. A short written update when something significant occurs — a regulatory interaction, an enrollment problem, a departure, an unexpected result — costs management very little and buys enormous trust. The corollary is that directors should be reachable and should not treat an off-cycle message as an imposition.

There is a limit on the other side. A board that demands constant updates, or whose individual directors contact management frequently with their own questions, becomes a drag on a small team's capacity. The chair has a role here in consolidating board questions and in protecting management from being managed by five people at once. In a company with a dozen employees, the executive team's time is among the scarcest resources the company has, and the board consumes it.


How This Changes as the Company Matures

The format that works for a Series A company with one program does not work for a company running a pivotal trial, and neither works for a public company.

Early on, meetings are small, informal, and heavily focused on financing and development progress. The board can reasonably function as a committee of the whole. As the company moves into later-stage clinical work, the volume of material grows past what a full board can absorb in a single meeting, and the committee structure has to take real weight — which in turn changes the board meeting, because committee chairs now report and the full board engages with their conclusions rather than the underlying detail.

Preparing for a public listing changes it again. Meeting materials become discoverable in a way private materials largely were not. Minutes become more consequential. Executive sessions of independent directors become an expectation rather than a choice. Disclosure obligations mean the board's awareness of material information carries consequences it did not previously carry. A board that has run disciplined meetings, kept real minutes, and held routine executive sessions arrives at that transition with habits that already fit. A board that has run loose meetings for five years has to change everything at once, during a period when it is also trying to complete an offering.

That is the practical argument for taking meeting mechanics seriously well before they are externally required: the habits take years to form and cannot be retrofitted quickly.


The Underlying Principle

A board meeting is the only moment when a board exists as a board rather than as a list of names. Everything else — the composition decisions, the committee charters, the chair structure — is preparation for what happens in those few hours, several times a year.

Most of what makes those hours productive is unexciting and entirely within the board's control. Send the materials far enough ahead that people can read them. Write them to inform a decision rather than to support a conclusion. Let the chair own the agenda. Put the hard thing first and give it real time. Spend the meeting discussing rather than being presented to. Hold executive sessions routinely enough that they mean nothing, so they are available when they must mean something. Write down what was decided and why, while it is fresh.

None of this requires more directors, more expertise, or more meetings. It requires treating the meeting as something designed rather than inherited. Boards that do tend to be the ones that catch problems a quarter earlier, make decisions they can explain afterward, and arrive at the company's hardest moments already knowing how to work together.

Continue Reading

Stay Informed

Governance insights delivered to your inbox. No spam.